$241 Million is the total value of Stonepine Capital Management, LLC's 28 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 47.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMYT | Buy | AMRYT PHARMA PLC - SPNR ADRsponsored ads | $52,417,000 | -20.0% | 6,338,200 | +4.4% | 21.74% | -27.7% |
| CTIC | Sell | CTI BIOPHARMA CORP | $21,876,000 | +0.2% | 4,684,404 | -46.8% | 9.07% | -9.4% |
| Buy | XERIS BIOPHARMA HOLDINGS INC | $20,286,000 | +22.4% | 7,924,056 | +40.1% | 8.41% | +10.6% | |
| AMRN | New | AMARIN CORP PLC -ADRspons adr new | $16,163,000 | – | 4,912,714 | +100.0% | 6.70% | – |
| OVID | Buy | OVID THERAPEUTICS INC | $13,245,000 | +3.0% | 4,218,069 | +5.3% | 5.49% | -6.9% |
| ADMA | Sell | ADMA BIOLOGICS INC | $13,051,000 | -6.6% | 7,131,808 | -28.0% | 5.41% | -15.6% |
| ATRS | Buy | ANTARES PHARMA INC | $12,834,000 | +56.5% | 3,130,192 | +36.3% | 5.32% | +41.4% |
| CFMS | Buy | CONFORMIS INC | $10,780,000 | -4.1% | 17,281,386 | +17.0% | 4.47% | -13.4% |
| APEN | Buy | APOLLO ENDOSURGERY INC | $10,248,000 | +5.6% | 1,693,834 | +47.1% | 4.25% | -4.6% |
| XGN | Buy | EXAGEN INC | $9,002,000 | -9.8% | 1,121,040 | +30.6% | 3.73% | -18.5% |
| ENTA | New | ENANTA PHARMACEUTICALS INC | $8,540,000 | – | 119,972 | +100.0% | 3.54% | – |
| LGND | New | LIGAND PHARMACEUTICALS | $8,291,000 | – | 73,700 | +100.0% | 3.44% | – |
| OPTN | Sell | OPTINOSE INC | $7,228,000 | +16.1% | 2,926,416 | -23.9% | 3.00% | +4.9% |
| QDEL | New | QUIDEL CORP | $6,949,000 | – | 61,791 | +100.0% | 2.88% | – |
| EOLS | Sell | EVOLUS INC | $6,577,000 | -45.8% | 586,224 | -68.5% | 2.73% | -51.0% |
| LIFE | Buy | ATYR PHARMA INC | $3,218,000 | -18.0% | 601,580 | +14.5% | 1.34% | -25.9% |
| DMAC | Buy | DIAMEDICA THERAPEUTICS INC | $2,993,000 | -32.8% | 1,197,245 | +0.2% | 1.24% | -39.3% |
| SYBX | SYNLOGIC INC | $2,554,000 | -0.8% | 1,064,135 | 0.0% | 1.06% | -10.4% | |
| RZLT | Sell | REZOLUTE INC | $2,531,000 | -34.5% | 748,702 | -7.4% | 1.05% | -40.8% |
| URGN | New | UROGEN PHARMA LTD | $2,342,000 | – | 268,833 | +100.0% | 0.97% | – |
| SRGA | New | SURGALIGN HOLDINGS INC | $2,244,000 | – | 7,375,678 | +100.0% | 0.93% | – |
| CELC | CELCUITY INC | $2,239,000 | -29.1% | 239,433 | 0.0% | 0.93% | -35.9% | |
| CDTX | Buy | CIDARA THERAPEUTICS INC | $2,079,000 | -29.2% | 2,496,520 | +8.0% | 0.86% | -36.0% |
| XOMA | Sell | XOMA CORP | $1,030,000 | +7.3% | 36,803 | -20.0% | 0.43% | -3.2% |
| AERI | New | AERIE PHARMACEUTICALS INC | $854,000 | – | 93,900 | +100.0% | 0.35% | – |
| ANIP | Sell | ANI PHARMACEUTICALS INC | $733,000 | -69.6% | 26,060 | -50.2% | 0.30% | -72.5% |
| New | MARINUS PHARMACEUTICALS INC | $531,000 | – | 56,747 | +100.0% | 0.22% | – | |
| NMTC | Sell | NEUROONE MEDICAL TECHNOLOGIE | $273,000 | -71.8% | 248,105 | -50.2% | 0.11% | -74.5% |
| ALDX | Exit | ALDEYRA THERAPEUTICS INC | $0 | – | -200,000 | -100.0% | -0.37% | – |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -300,000 | -100.0% | -0.46% | – |
| Exit | AVALO THERAPEUTICS INC | $0 | – | -1,510,095 | -100.0% | -1.18% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.